phentermine gh phentermine 15 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine gh phentermine 40 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 40 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; purified water; erythrosine; gelatin; iron oxide black; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine gh phentermine 30 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 30 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; brilliant blue fcf; erythrosine; gelatin; iron oxide black - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
alenami phentermine (as hydrochloride) 40 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
alenami phentermine (as hydrochloride) 30 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 37.34 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
alenami phentermine (as hydrochloride) 15 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 18.67 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; quinoline yellow; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentodur phentermine (as hydrochloride) 40 mg modified release capsule blister pack
arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 49.776 mg - capsule, modified release - excipient ingredients: liquid paraffin; lactose monohydrate; magnesium stearate; iron oxide black; sodium polystyrene sulfonate; sunset yellow fcf; titanium dioxide; gelatin; erythrosine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentodur phentermine (as hydrochloride) 30 mg modified release capsule blister pack
arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 37.332 mg - capsule, modified release - excipient ingredients: gelatin; liquid paraffin; magnesium stearate; titanium dioxide; sodium polystyrene sulfonate; iron oxide red; lactose monohydrate; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentodur phentermine (as hydrochloride) 15 mg modified release capsule blister pack
arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 18.666 mg - capsule, modified release - excipient ingredients: gelatin; sodium polystyrene sulfonate; iron oxide black; lactose monohydrate; brilliant blue fcf; titanium dioxide; magnesium stearate; iron oxide yellow; liquid paraffin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine sandoz phentermine (as hydrochloride) 40 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.